| Note |
A major advance in antipsychotic therapy. Roxiam (remoxipride) is a new antipsychotic which is the result of intensive CNS research by Astra Pharmaceuticals. Roxiam, a selective dopamine-D2 receptor antagonist, was developed to provide an optimal therapeutic effect together with a favourable side-effect profile. Roxiam has been shown to be an effective antipsychotic with efficacy equivalent to that of haloperidol in the treatment of schizophrenia. Due to the selective activity of remoxipride on the D2 receptor, clinical trials have clearly established Roxiam as an agent which has substantially less extrapyramidal involvement, a lower incidence of central nervous system effects and a minimal sedative potential compared to classical antipsychotics. Roxiam, Widening the margin between efficacy and side effects. Roxiam. The D2 specific antipsychotic. |
